Overactive BladderNCT00943735
This Is An Open-Label Study To Evaluate Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive Bladder
An observational study of Overactive Bladder, run by Pfizer.
Trial summary
The primary objective of the study is to assess the level of medication adherence observed among subjects receiving a specific combination of education and support materials (YourWay plan) along with a prescription for fesoterodine. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Overactive Bladder
- What is being tested?
- Fesoterodine and Your Way
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 774 participants
- Where
- No sites listed yet
- Study dates
- Jul 2009to Nov 2010
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: fesoterodine-naïve subjects with OAB symptoms present during regularly-scheduled physician visits
Who may be able to join
- Male or female outpatients >=18 years old
- Eligible for receiving Toviaz 4mg or 8mg QD treatment based on the approved US label.
Who cannot join
- Female subjects who are pregnant, lactating, or who are intending to become pregnant within 28 days after the completion of the study (use of contraceptives is not required to participate in the study)
- Have participated in any other studies involving study drugs within 30 days prior to entry in the study
- Subjects who have previously taken fesoterodine.
About this study
Official title: A 13-Week, Single-Arm, Open-Label, Multicenter Study To Evaluate Refill Adherence And Satisfaction With Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive Bladder.
The primary objective of the study is to assess the level of medication adherence observed among subjects receiving a specific combination of education and support materials (YourWay plan) along with a prescription for fesoterodine.
Read the detailed description
This is a non-interventional, observational study. Study investigators will recruit symptomatic, fesoterodine-naïve subjects when they present with OAB symptoms during regularly-scheduled physician visits fesoterodine-naïve subjects with OAB symptoms present during regularly-scheduled physician visits
- Conditions
- Overactive Bladder
- Being tested
- Fesoterodine, Your Way
- Keywords
- Overactive Bladder Incontinence Adherence Behavioral interventions
- Medical subject headings
- Urinary Bladder, Overactive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FesoterodineDrug
Fesoterodine 4 mg and 8 mg QD
Your WayBehavioural
early intervention after treatment initiation and before patients have an opportunity to discontinue medication; reinforcing the treatable nature of OAB
| Study group | Role | What they receive |
|---|---|---|
| Fesoterodine arm | subjects who present with OAB symptoms during medical office visits and who appear to be candidates for fesoterodine therapy Receives: Drug: Fesoterodine; Behavioral: Your Way |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants Who Filled at Least 90 Days Supply of Fesoterodine (4mg QD or 8mg QD) Within 90 Days of Study Enrollment
Prototypical pattern for meeting primary endpoint was to fill 3 separate prescriptions (Rx), each for a 30-day supply between enrollment and Day 90. Rx fills could happen as early as Day 0, 30, and 60 of the study period. Participants could also have chosen to wait until their 14-day medication sample was exhausted before receiving their first fill. Investigators received no prescribing restrictions, but were advised not to write Rx for a 90-day supply of fesoterodine at enrollment visit. Participants whose first observed Rx was for a ≥90-day supply were non-evaluable for the primary endpoint.
Measured: Enrollment (Day 0) up to 90 days
Secondary outcomes (29)
Percentage of Participants Who Filled at Least One Fesoterodine Prescription During the Study Period (Primary Adherence)
The prototypical pattern was to fill 3 separate prescriptions, each for a 30-day supply, between the enrollment date and Day 90 of the study period; these prescription fills could happen as early as Day 0, 30, and 60 of the study period. Primary adherence was met if the participant filled at least 1 fesoterodine prescription during the study period.
Measured: Enrollment (Day 0) up to 90 days
Percentage of Participants Who Filled at Least Two Fesoterodine Prescriptions (First Refill) During the Study Period
The prototypical pattern was to fill 3 separate prescriptions, each for a 30-day supply, between the enrollment date and Day 90 of the study period; these prescription fills could happen as early as Day 0, 30, and 60 of the study period. At enrollment, the Investigator provided participants with a prescription for fesoterodine 4mg or 8mg to be filled at a pharmacy of their choice. The first refill indicated that 2 fesoterodine prescriptions had been filled.
Measured: Enrollment (Day 0) up to 90 days
Percentage of Participants Who Visited the YourWay Website
YourWay plan was available and accessible to all participants prescribed fesoterodine, but was not defined as an explicit or required component. Plan included motivational support for taking fesoterodine and behavioral interventions shown in clinical studies to improve participants' Overactive Bladder (OAB) outcomes. Objectives included intervening quickly after treatment initiation, before participants had an opportunity to discontinue medication, reinforcing the treatable nature of OAB, and setting appropriate expectations for onset of action with therapy and degree of symptom improvement.
Measured: Baseline up to 90 days
Among Participants Who Used the YourWay Website, the Percentage of Participants Who Agreed That the Website Was Useful
Measured: Baseline up to 90 days
Percentage of Participants Who Reported Having Read the YourWay Plan Materials Received From Their Physician or From the Resource Kit
YourWay plan included a starter pack with a 14-day supply of 4 mg or 8 mg fesoterodine; guidebook for YourWay plan components and lifestyle modification tips; plan progress tracker with additional lifestyle tips; plan enrollment form. About 1 week after plan enrollment, participants received a resource kit by mail which included: a cover letter; brochures for "Core 4" elements (food and drink, teach your bladder, daily fesoterodine, and track your progress); bladder diary and "track your progress" brochure; and recipes using bladder-friendly foods.
Measured: Baseline up to 90 days
Percentage of Participants Who Reported Having Adopted Lifestyle Changes to Help Improve Their Overactive Bladder (OAB) Symptoms
The use of the YourWay plan was optional but was available to all participants and included guidance for food and drink choices, bladder training, treatment compliance, and use of a daily tracker.
Measured: Baseline up to 90 days
Percentage of Participants Who Reported That They Made Bladder-friendly Food and Drink Choices
The use of the YourWay plan was optional but was available to all participants and included bladder-friendly food and drink choices and recipes as well as information for maintaining hydration and avoidance of potential bladder irritants (such as caffeine, citrus fruits and juices, artificial sweeteners, tomato-based foods, soda, alcohol, and spicy foods).
Measured: Baseline up to 90 days
Percentage of Participants Who Reported That They Trained Their Bladder to "Wait"
The use of the YourWay plan was optional but was available to all participants and included bladder training techniques such as to urinate each day when getting up and before going to bed, gradually increasing the amount of time between urinating, staying with timing goals whether there was a need to urinate or not, and bladder control tips (such as pelvic floor muscle squeeze, sit down and take 5 deep breaths, or stating "I'm the boss - not my bladder").
Measured: Baseline up to 90 days
Percentage of Participants Who Reported That They Took Toviaz® (Fesoterodine) as Directed
Measured: Baseline up to 90 days
Percentage of Participants Who Reported That They Recorded Their Treatment Goals in the Daily Core 4 Tracker
YourWay Daily Core 4 Tracker to track daily progress in the 4 core areas of food and drink (make more informed choices), teach your bladder (train your bladder to "wait"), daily Toviaz® (always take as directed), and keep track (share with your doctor).
Measured: Baseline up to 90 days
Percentage of Participants Who Reported That They Kept Track of Symptoms in the 12 Week Tracker Bladder Diary
For each week, the 12 Week Tracker included a participant determined weekly goal, a reminder to fill the prescription (if appropriate interval), participant reported progress in response to "this week I did well at", and a 7-day Daily Core 4 Tracker checklist (food and drink, teach your bladder, daily fesoterodine, and track your progress).
Measured: Baseline up to 90 days
Percentage of Participants Who Reported That They Let Their Doctor Know How They Were Doing With the YourWay Plan
Participants were recruited for study participation when they presented with OAB symptoms during regularly-scheduled physician visits; screening and enrollment occurred during the same visit. Follow-up visits could be scheduled per standard clinical practice.
Measured: Baseline up to 90 days
Percentage of Participants Who Agreed That They Found the YourWay Program Materials Easy to Understand
Measured: Baseline up to 90 days
Percentage of Participants Who Agreed That the YourWay Program Provided a Good Amount of Information
Measured: Baseline up to 90 days
Percentage of Participants Who Agreed That the YourWay Plan Provided a Strong Support System That Participants Could Count on for Information and Advice
YourWay participants received 6 telephone calls from an automated speech-recognition system over a period of approximately 11 weeks. The calls included reinforcement of treatment participation, treatment expectations, compliance, general health messages regarding OAB, review of training materials, optional weekly email communication, and a wrap-up call which included a summary of lessons learned from each of the Core 4 lessons calls and guidance to find additional information about medication and lifestyle tips to support management of OAB symptoms.
Measured: Baseline up to 90 days
Percentage of Participants Who Agreed That They Were Able to Incorporate the YourWay Plan Into Their Lives
Measured: Baseline up to 90 days
Percentage of Participants Who Agreed That the YourWay Plan Helped Them Play a More Active Role in Managing Their Condition
Measured: Baseline up to 90 days
Percentage of Participants Who Agreed That They Understood What to Expect From Their OAB Medication, Toviaz® (Fesoterodine)
Product indication and safety information was provided to all participants by the investigator and / or within the YourWay plan program information.
Measured: Baseline up to 90 days
Percentage of Participants Who Agreed That They Learned Something About Their Condition
Measured: Baseline up to 90 days
Percentage of Participants Who Agreed That They Increased Their Knowledge of Healthy Bladder Behaviors
The use of the YourWay plan was optional but was available to all participants and included healthy bladder behaviors such as setting and maintaining personal goals and choice of bladder-friendly food and drinks.
Measured: Baseline up to 90 days
Percentage of Participants Who Agreed That They Understand OAB is a Chronic Condition That Can be Successfully Managed, But Generally Not Cured
Measured: Baseline up to 90 days
Percentage of Participants Who Reported They Felt Confident That They Could Manage Their OAB as a Result of the YourWay Plan
Measured: Baseline up to 90 days
Percentage of Participants Who Reported They Were Satisfied With the Overall Content of the YourWay Plan
Measured: Baseline up to 90 days
Percentage of Participants Who Reported They Were Satisfied With the Participant Support Telephone Calls
YourWay participants received 6 telephone calls from an automated speech-recognition system over a period of approximately 11 weeks. The calls included reinforcement of treatment participation, treatment expectations, compliance, general health messages regarding OAB, review of training materials, optional weekly email communication, and a wrap-up call which included a summary of lessons learned from each of the Core 4 lessons calls and guidance to find additional information about medication and lifestyle tips to support management of OAB symptoms.
Measured: Baseline up to 90 days
Percentage of Participants Who Reported They Were Satisfied With the Treatment Goals and Bladder Symptoms Progress Trackers
Treatment goals and bladder symptoms progress trackers were incorporated in the 12 Week Tracker which included a participant determined weekly goal, a reminder to fill the prescription (if appropriate interval), participant reported progress in response to "this week I did well at", and a 7-day Daily Core 4 Tracker checklist (food and drink, teach your bladder, daily fesoterodine, and track your progress).
Measured: Baseline up to 90 days
Percentage of Participants Who Reported They Were Satisfied With Their Physician
Measured: Baseline up to 90 days
Percentage of Participants Who Reported the YourWay Plan Encouraged Their Use of Toviaz® (Fesoterodine)
Measured: Baseline up to 90 days
Percentage of Participants Who Agreed That They Had a Good Understanding About Their Condition and How to Treat it
Measured: Baseline up to 90 days
Comparison of Percentage of Participants Who Agreed That They Had a Good Understanding About Their Condition and How to Treat it, Between Enrollment Date and End of Study CATI Interview
Measured: Enrollment (Day 0) up to 90 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2009 (estimated)
- Study startJul 2009
- Primary completionNov 2010
- Study completionNov 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Overactive BladderStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 774 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00943735
- Sponsor's protocol ID
- A0221078
- Status last verified
- Nov 2018
- First submitted
- 20 Jul 2009
- Last updated
- 4 Dec 2018
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Dec 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A 13-Week, Single-Arm, Open-Label, Multicenter Study To Evaluate Refill Adherence And Satisfaction With Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive Bladder.
- ClinicalTrials.gov ID
- NCT00943735
- Acronym / sponsor ID
- A0221078
- Conditions
- Overactive Bladder
- Keywords
- Overactive Bladder Incontinence Adherence Behavioral interventions
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 774 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- Jul 2009
- Primary completion
- Nov 2010 (actual)
- Study completion
- Nov 2010 (actual)
- First posted
- 22 Jul 2009 (estimated)
- Results
- Posted 15 Mar 2012
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of the study is to assess the level of medication adherence observed among subjects receiving a specific combination of education and support materials (YourWay plan) along with a prescription for fesoterodine.
Detailed description
This is a non-interventional, observational study. Study investigators will recruit symptomatic, fesoterodine-naïve subjects when they present with OAB symptoms during regularly-scheduled physician visits fesoterodine-naïve subjects with OAB symptoms present during regularly-scheduled physician visits
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Fesoterodine arm | – | Drug: Fesoterodine, Behavioral: Your Waysubjects who present with OAB symptoms during medical office visits and who appear to be candidates for fesoterodine therapy |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- fesoterodine-naïve subjects with OAB symptoms present during regularly-scheduled physician visits
Key inclusion criteria (2 listed)
- Male or female outpatients >=18 years old
- Eligible for receiving Toviaz 4mg or 8mg QD treatment based on the approved US label.
Key exclusion criteria (3 listed)
- Female subjects who are pregnant, lactating, or who are intending to become pregnant within 28 days after the completion of the study (use of contraceptives is not required to participate in the study)
- Have participated in any other studies involving study drugs within 30 days prior to entry in the study
- Subjects who have previously taken fesoterodine.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FesoterodineFesoterodine 4 mg and 8 mg QD | Drug | Fesoterodine arm |
| Your Wayearly intervention after treatment initiation and before patients have an opportunity to discontinue medication; reinforcing the treatable nature of OAB | Behavioural | Fesoterodine arm |
Primary outcome
Percentage of Participants Who Filled at Least 90 Days Supply of Fesoterodine (4mg QD or 8mg QD) Within 90 Days of Study Enrollment
Time frame: Enrollment (Day 0) up to 90 days
Prototypical pattern for meeting primary endpoint was to fill 3 separate prescriptions (Rx), each for a 30-day supply between enrollment and Day 90. Rx fills could happen as early as Day 0, 30, and 60 of the study period. Participants could also have chosen to wait until their 14-day medication sample was exhausted before receiving their first fill. Investigators received no prescribing restrictions, but were advised not to write Rx for a 90-day supply of fesoterodine at enrollment visit. Participants whose first observed Rx was for a ≥90-day supply were non-evaluable for the primary endpoint.
29 secondary outcomes
Percentage of Participants Who Filled at Least One Fesoterodine Prescription During the Study Period (Primary Adherence)
Time frame: Enrollment (Day 0) up to 90 days
Percentage of Participants Who Filled at Least Two Fesoterodine Prescriptions (First Refill) During the Study Period
Time frame: Enrollment (Day 0) up to 90 days
Percentage of Participants Who Visited the YourWay Website
Time frame: Baseline up to 90 days
Among Participants Who Used the YourWay Website, the Percentage of Participants Who Agreed That the Website Was Useful
Time frame: Baseline up to 90 days
Percentage of Participants Who Reported Having Read the YourWay Plan Materials Received From Their Physician or From the Resource Kit
Time frame: Baseline up to 90 days
Percentage of Participants Who Reported Having Adopted Lifestyle Changes to Help Improve Their Overactive Bladder (OAB) Symptoms
Time frame: Baseline up to 90 days
Percentage of Participants Who Reported That They Made Bladder-friendly Food and Drink Choices
Time frame: Baseline up to 90 days
Percentage of Participants Who Reported That They Trained Their Bladder to "Wait"
Time frame: Baseline up to 90 days
Percentage of Participants Who Reported That They Took Toviaz® (Fesoterodine) as Directed
Time frame: Baseline up to 90 days
Percentage of Participants Who Reported That They Recorded Their Treatment Goals in the Daily Core 4 Tracker
Time frame: Baseline up to 90 days
Percentage of Participants Who Reported That They Kept Track of Symptoms in the 12 Week Tracker Bladder Diary
Time frame: Baseline up to 90 days
Percentage of Participants Who Reported That They Let Their Doctor Know How They Were Doing With the YourWay Plan
Time frame: Baseline up to 90 days
Percentage of Participants Who Agreed That They Found the YourWay Program Materials Easy to Understand
Time frame: Baseline up to 90 days
Percentage of Participants Who Agreed That the YourWay Program Provided a Good Amount of Information
Time frame: Baseline up to 90 days
Percentage of Participants Who Agreed That the YourWay Plan Provided a Strong Support System That Participants Could Count on for Information and Advice
Time frame: Baseline up to 90 days
Percentage of Participants Who Agreed That They Were Able to Incorporate the YourWay Plan Into Their Lives
Time frame: Baseline up to 90 days
Percentage of Participants Who Agreed That the YourWay Plan Helped Them Play a More Active Role in Managing Their Condition
Time frame: Baseline up to 90 days
Percentage of Participants Who Agreed That They Understood What to Expect From Their OAB Medication, Toviaz® (Fesoterodine)
Time frame: Baseline up to 90 days
Percentage of Participants Who Agreed That They Learned Something About Their Condition
Time frame: Baseline up to 90 days
Percentage of Participants Who Agreed That They Increased Their Knowledge of Healthy Bladder Behaviors
Time frame: Baseline up to 90 days
Percentage of Participants Who Agreed That They Understand OAB is a Chronic Condition That Can be Successfully Managed, But Generally Not Cured
Time frame: Baseline up to 90 days
Percentage of Participants Who Reported They Felt Confident That They Could Manage Their OAB as a Result of the YourWay Plan
Time frame: Baseline up to 90 days
Percentage of Participants Who Reported They Were Satisfied With the Overall Content of the YourWay Plan
Time frame: Baseline up to 90 days
Percentage of Participants Who Reported They Were Satisfied With the Participant Support Telephone Calls
Time frame: Baseline up to 90 days
Percentage of Participants Who Reported They Were Satisfied With the Treatment Goals and Bladder Symptoms Progress Trackers
Time frame: Baseline up to 90 days
Percentage of Participants Who Reported They Were Satisfied With Their Physician
Time frame: Baseline up to 90 days
Percentage of Participants Who Reported the YourWay Plan Encouraged Their Use of Toviaz® (Fesoterodine)
Time frame: Baseline up to 90 days
Percentage of Participants Who Agreed That They Had a Good Understanding About Their Condition and How to Treat it
Time frame: Baseline up to 90 days
Comparison of Percentage of Participants Who Agreed That They Had a Good Understanding About Their Condition and How to Treat it, Between Enrollment Date and End of Study CATI Interview
Time frame: Enrollment (Day 0) up to 90 days
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Dec 2018.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Overactive Bladder
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Active, not recruitingPhase 2/3
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
Urinary Incontinence, Overactive Bladder Syndrome
Recruiting
UCon Treatment of Overactive Bladder (OAB) in Males
Urinary Incontinence, Urge Incontinence
Active, not recruitingObservational study
Overactive Bladder Symptoms and Urinary Incontinence In Women With Rheumatoid Arthritis
Rheumatoid Arthritis, Rheumatoid Arthritis (RA)
RecruitingObservational study
Predictive Value of Inflammatory Biomarkers for Mirabegron Response in Women With Overactive Bladder
Overactive Bladder (OAB)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
Questions about this trial
What is this clinical trial studying?
An observational study of Overactive Bladder, run by Pfizer.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Dec 2018. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 15 Mar 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants Who Filled at Least 90 Days Supply of Fesoterodine (4mg QD or 8mg QD) Within 90 Days of Study Enrollment (time frame: Enrollment (Day 0) up to 90 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2018.